National Cancer Institute Awarded Envisagenics $2 Million
The two-year grant supports the development of an AI-driven machine learning algorithm for cancer therapy discovery.
Updated on Oct. 13, 2026 in Biotech

Live Poll
Should the government prioritize funding for private AI-driven research to develop new cancer therapies?
The National Cancer Institute awarded New York-based Envisagenics a $2 million Direct to Phase II Small Business Innovation Research grant. The funding will support the development and commercialization of the company's new SpliceDisco machine learning algorithm over the next two years.
Why it matters
This grant aims to accelerate the discovery of first-in-class cancer therapeutics by combining AI-driven target prioritization with experimental validation. It enables the company to scale its RNA splicing platform to identify potential new treatment targets.
The project leverages SpliceCore, a proprietary platform that analyzes 14 million distinct RNA splicing events. It integrates machine learning with large-scale transcriptomic analysis to validate potential therapeutic targets.
The players
Envisagenics
A New York-based biotechnology company that utilizes artificial intelligence and transcriptomic analysis to identify RNA splicing therapeutics.
National Cancer Institute
The federal government's primary agency for cancer research, responsible for funding initiatives focused on identifying new therapeutic pathways.
The details
The SpliceDisco algorithm is designed to refine the process of identifying RNA splicing errors—mutations in the process where cells assemble genetic instructions—that drive oncogenesis. By integrating AI-driven target prioritization with experimental wet-lab validation, the platform narrows down potential therapeutic interventions. This approach moves beyond traditional analysis by automating the cross-referencing of splicing datasets with biological outcomes.
Timeline
October 13, 2026: Envisagenics announced the receipt of the grant award.
Two-year duration: The grant funds the project's development and commercialization timeline.
The Tech Race
The NCI's grant underscores a sector-wide push to modernize cancer research through computational biology and large-scale data mining. Envisagenics competes in a landscape of AI-enabled biotech firms, such as those leveraging similar transcriptomic datasets to secure early-stage drug development milestones.
This grant does not immediately change clinical care or existing cancer treatment protocols. Instead, it funds the backend research and development required to identify future therapeutic candidates that may enter clinical pipelines in the coming years.
The takeaway
This funding provides the necessary capital to transition the SpliceDisco algorithm from a research prototype to a commercialized tool. Observers should track the release of preliminary target discovery data, which will demonstrate the platform's efficacy compared to current standard manual methods.
Further reading
For broader context on the evolution of AI-driven drug discovery, see the latest updates in our Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should the government prioritize funding for private AI-driven research to develop new cancer therapies?





